| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.094 | 0.03 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.069 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.06 | 0.2 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.054 | 0.2 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.047 | 0.4 |